Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Practical Approach to the Diagnosis and Management of Cutaneous Graft Versus Host Disease
Description
In this presentation on the diagnosis and management of cutaneous graft versus host disease (GVHD), Dr. Sylvina Puglisi and Dr. Jasmine Rana emphasize the critical role dermatologists play in the care of patients undergoing stem cell transplantation. Dr. Puglisi provides an overview of stem cell transplants and discusses the rise of GVHD cases correlated with enhanced patient survival and the need for dermatologists to distinguish GVHD from other skin conditions. Acute GVHD, which can appear 7-100 days post-transplant, typically presents as a mobiliform rash often accompanied by systemic symptoms indicating organ involvement. The discussion progresses to chronic GVHD, which can develop after acute GVHD or emerge independently. Chronic GVHD presents with diverse symptoms across multiple organ systems and challenges in diagnosis and management. The speakers stress the significance of timely and accurate diagnosis, as it impacts treatment effectiveness and patient quality of life. They share clinical cases to illustrate common presentations and the importance of recognizing mimickers of GVHD, emphasizing collaboration with oncology teams. Recent advancements in FDA-approved treatments give hope for better management of chronic GVHD. The session concludes with a reminder of the vital contribution of dermatology in this complex medical field.
View moreConclusions
- Dermatologists play an essential role in the management and diagnosis of graft versus host disease (GVHD) in transplant patients.
- GVHD is a significant cause of non-relapse mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) patients, with a substantial risk of developing acute GVHD post-transplant.
- The risk of developing acute GVHD can reach up to 50% within two years following transplant, primarily affecting the skin, liver, and gastrointestinal tract.
- Acute GVHD can occur beyond the typical 100-day post-transplant period, indicating the need for ongoing monitoring and assessment.
- Diagnosis of acute GVHD relies heavily on clinical presentation and morphology of the rash, as well as the involvement of other organs.
- Skin manifestations of GVHD often include a morbilliform rash with predilection for acral skin, alongside systemic symptoms such as diarrhea and liver involvement.
- Differentiation between acute GVHD and other post-transplant skin conditions (such as drug reactions and viral exanthems) is crucial for effective management.
- Treatment strategies for skin-directed acute GVHD involve topical agents, systemic corticosteroids, and adjunct therapies like extracorporeal photophoresis and narrowband UVB phototherapy.
- Chronic GVHD represents a different disease entity characterized by unique clinical features, including fibrosis and varied organ system involvement, requiring distinct management approaches.
- The importance of HLA compatibility in donor-recipient pairing cannot be overstated, as it remains the most significant predictor of GVHD development.
- Hymes, K. B., et al. (2012). Practical approaches to the treatment of complications of cutaneous Graft versus Host Disease. Journal of the American Academy of Dermatology, 66(4), 515.
- Bashir, Q., Shpall, E. J., & Champlin, R. E. (2025). Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Blood, 145(8), 795-800.
- Spaccarelli, N. (2018). Acute GVHD. In M. Rosenbach (Ed.), Inpatient Dermatology. J Am Acad Dermatol.
- Ghimire, S., et al. (2017). The Role of Microbiota in the Pathogenesis of Graft Versus Host Disease. Frontiers in Immunology, 8, 79.
- Calhoun, M. A., et al. (2022). The Acute Skin Graft-versus-Host Disease Diagnosis and Management. International Journal of Dermatology, 61(8), e299-e301.
- Baumrin, E., et al. (2024). Chronic Graft-versus-Host Disease: Epidemiology, Pathogenesis, and Clinical Manifestations. J Am Acad Dermatol.
- Hunjan, A., et al. (2019). Chemotherapeutic Agents Associated with Toxic Erythema: A Comparative Study. Hematol Oncol Stem Cell Ther, 12(1), 19-25.
- Martires, K. J., et al. (2011). Pathologic and Clinical Features of Graft-Versus-Host Disease. Arch Dermatol, 147(9), 1081-1086.
- Shi, C. R., et al. (2024). Graft-Versus-Host Disease: A Polymorphous Skin Disorder. Transplant Cell Ther, 30(9S), S513-S533.
- Lee, S. J., & Zeiser, R. (2025). Chronic Graft-Versus-Host Disease Treatment Options. Blood, 145(8), 795-800.